查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1575458

腦病變市場：依疾病類型、治療類型、最終使用者、嚴重程度、年齡層、診斷方法、應用、病理生理學 - 2025-2030 年全球預測

Encephalopathy Market by Disease Type, Treatment Type, End-User, Severity, Age Group, Diagnosis Method, Application, Pathophysiology - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年腦病變市場價值為1.8534億美元，預計到2024年將達到1.9685億美元，複合年成長率為6.15%，預計到2030年將達到2.8153億美元。

腦病變是指一系列導致大腦功能和結構改變的腦部疾病，通常以精神狀態改變、精神錯亂和記憶障礙為特徵。解決腦病變的需求對患者的生活品質和醫療保健成本產生重大影響，推動了對創新診斷方法、治療方法和管理解決方案的需求。腦病變主要應用於醫療保健領域，例如醫院、神經診所和復健中心。旨在開發新治療方法的製藥公司和研究機構也使用它。市場成長受到神經系統疾病盛行率上升、老年人口增加、診斷技術進步等因素的顯著影響。最近的趨勢正在增加個人化醫療的重要性，並為標靶治療提供了巨大的機會。此外，將人工智慧整合到診斷程序中以及使用生物標記進行早期檢測提供了潛在的成長途徑。然而，挑戰包括高昂的治療成本、發展中地區缺乏認知以及複雜的法律規範。此外，KEYWORD 的多維性質使診斷和治療變得複雜，需要強力的臨床研究和跨學科合作。為了利用市場開拓機會，該公司正在開發具有成本效益的攜帶式診斷設備，投資於標靶治療的研發，並利用數位健康解決方案來改善治療的可及性。生物標記研究和遠端醫療的創新也可能提供競爭優勢。該市場的特點是技術進步迅速，但也面臨激烈的競爭和嚴格的監管。公司應優先考慮策略夥伴關係、併購，以加強其市場地位。透過創新和策略擴張來應對這些挑戰，腦病變市場擁有充足的成長空間，為願意適應和投資尖端研發的公司提供了巨大的潛力。

主要市場統計
基準年[2023] 1.8534 億美元
預測年份 [2024] 1.9685億美元
預測年份 [2030] 28153萬美元
複合年成長率（%） 6.15%

市場動態：揭示快速發展的腦病變市場的關鍵市場洞察

供需的動態交互作用正在改變腦病變市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 開發和提供用於準確檢測腦病變的專用診斷工具
    • 個人化醫療在調整腦病變患者治療策略中的作用
    • 糖尿病和高血壓等慢性病對腦病變率和治療的影響
    • 將人工智慧融入神經系統疾病的診斷和進展預測
  • 市場限制因素
    • 治療和診斷費用高
  • 市場機會
    • 人工智慧在各種腦病變診斷中的整合
    • 全面的病患教育計劃，以提高對腦病變治療的依從性
    • 開發用於遠距腦病變患者管理的遠端醫療平台
  • 市場挑戰
    • 疾病機制與診斷複雜性

波特的五力：駕馭腦病變市場的策略工具

波特的五力框架是了解腦病變市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解腦病變市場的外部影響

外部宏觀環境因素在塑造腦病變市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解腦病變市場的競爭狀況

對腦病變市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣腦病變市場供應商的績效評估

FPNV定位矩陣是評估腦病變市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製腦病變市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對腦病變市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 開發和提供用於準確檢測腦病變的專用診斷工具
      • 個人化醫療在腦病變患者客製化治療策略中的作用
      • 糖尿病和高血壓等慢性病對腦病變率和治療的影響
      • 將人工智慧融入神經系統疾病的診斷和進展預測
    • 抑制因素
      • 治療和診斷費用高
    • 機會
      • 整合人工智慧診斷各種形式的腦病變
      • 全面的病患教育計劃，以提高治療依從性
      • 開發用於遠距患者管理的遠端醫療平台
    • 任務
      • 疾病機制與診斷複雜性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章腦病變市場：依疾病類型

  • 肝腦病變
  • 高血壓腦病變
  • 中毒性代謝性腦病變
  • 創傷腦病變
  • 尿毒症腦病變
  • 韋尼克腦病變

第7章腦病變市場：依治療類型

  • 藥品
    • 抗生素
    • 乳果糖
    • 益生菌
    • Rifaximin
  • 外科手術
    • 肝臟移植
    • 神經外科
  • 治療方法
    • 行為療法
    • 認知復健

第8章腦病變市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 調查機構
  • 專科診所

第9章腦病變市場：依嚴重程度

  • 急性腦病變
  • 慢性腦病變
  • 亞急性腦病變

第10章腦病變市場：依年齡層

  • 成人用
  • 老年病
  • 小兒科

第11章腦病變市場：依診斷方法

  • 驗血
  • 腦電圖（EEG）
  • 影像
    • 電腦斷層掃描
    • MRI
    • 超音波

第12章腦病變市場：依應用分類

  • 診斷
  • 研究
  • 治療性的

第13章腦病變市場：依病理生理學分類

  • 缺氧性腦病變
  • 缺氧缺血性腦病變

第14章北美和南美腦病變市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第15章亞太腦病變市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第16章歐洲、中東和非洲腦病變市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第17章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-535C62918A92

The Encephalopathy Market was valued at USD 185.34 million in 2023, expected to reach USD 196.85 million in 2024, and is projected to grow at a CAGR of 6.15%, to USD 281.53 million by 2030.

Encephalopathy refers to a broad spectrum of brain diseases leading to altered brain function and structure, often characterized by an altered mental state, confusion, and memory problems. The necessity of addressing encephalopathy lies in its significant impact on patients' quality of life and healthcare costs, driving demand for innovative diagnostic approaches, therapeutics, and management solutions. Encephalopathy finds application primarily in healthcare sectors, including hospitals, neurology clinics, and rehabilitation centers. End-use scopes also extend to pharmaceutical companies and research institutes aiming to develop novel treatments. The market's growth is largely influenced by factors such as the rising prevalence of neurological disorders, increasing geriatric population, and advancements in diagnostic technologies. Recent trends include the growing importance of personalized medicine, which opens up significant opportunities for targeted therapies. Moreover, the integration of artificial intelligence in diagnostic procedures and the use of biomarkers for early detection offer avenues for potential growth. However, limitations such as the high cost of treatment, lack of awareness in developing regions, and complex regulatory frameworks pose challenges. Additionally, the multidimensional nature of encephalopathy complicates diagnosis and treatment, necessitating robust clinical research and interdisciplinary collaboration. To capitalize on market opportunities, businesses can focus on developing cost-effective and portable diagnostic devices, investing in research for targeted therapies, and employing digital health solutions to enhance treatment accessibility. Innovations in biomarker research and telemedicine can also provide competitive advantages. The market is characterized by rapid technological advancements but faces intense competition and stringent regulations. Companies should prioritize strategic partnerships, mergers, and acquisitions to bolster their market position. By addressing these challenges through innovation and strategic expansion, there is ample room for growth in the encephalopathy market, offering substantial potential for companies willing to adapt and invest in cutting-edge research and development.

KEY MARKET STATISTICS
Base Year [2023] USD 185.34 million
Estimated Year [2024] USD 196.85 million
Forecast Year [2030] USD 281.53 million
CAGR (%) 6.15%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Encephalopathy Market

The Encephalopathy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Development and availability of specialized diagnostic tools for accurate encephalopathy detection
    • The role of personalized medicine in tailoring treatment strategies for encephalopathy patients
    • Impact of chronic diseases such as diabetes and hypertension on encephalopathy prevalence and management
    • Integration of artificial intelligence in diagnosing and predicting the progression of neurological disorders
  • Market Restraints
    • High cost of treatment and diagnostics
  • Market Opportunities
    • Integrating artificial intelligence in diagnosing various forms of encephalopathy
    • Comprehensive patient education programs to improve encephalopathy treatment adherence
    • Developing telemedicine platforms for remote encephalopathy patient management
  • Market Challenges
    • Complexity of disease mechanisms and diagnosis

Porter's Five Forces: A Strategic Tool for Navigating the Encephalopathy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Encephalopathy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Encephalopathy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Encephalopathy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Encephalopathy Market

A detailed market share analysis in the Encephalopathy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Encephalopathy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Encephalopathy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Encephalopathy Market

A strategic analysis of the Encephalopathy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Encephalopathy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca PLC, Bayer AG, Biogen Inc, Boehringer Ingelheim International GmbH, Eisai Co., Ltd., Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Roche Holdings AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Encephalopathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Hepatic Encephalopathy, Hypertensive Encephalopathy, Toxic-Metabolic Encephalopathy, Traumatic Encephalopathy, Uremic Encephalopathy, and Wernicke's Encephalopathy.
  • Based on Treatment Type, market is studied across Medications, Surgery, and Therapies. The Medications is further studied across Antibiotics, Lactulose, Probiotics, and Rifaximin. The Surgery is further studied across Liver Transplantation and Neurosurgery. The Therapies is further studied across Behavioral Therapy and Cognitive Rehabilitation.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Severity, market is studied across Acute Encephalopathy, Chronic Encephalopathy, and Subacute Encephalopathy.
  • Based on Age Group, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Diagnosis Method, market is studied across Blood Tests, Electroencephalogram (EEG), and Imaging. The Imaging is further studied across CT Scan, MRI, and Ultrasound.
  • Based on Application, market is studied across Diagnostic, Research, and Therapeutic.
  • Based on Pathophysiology, market is studied across Anoxic Encephalopathy and Hypoxic Ischemic Encephalopathy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Development and availability of specialized diagnostic tools for accurate encephalopathy detection
      • 5.1.1.2. The role of personalized medicine in tailoring treatment strategies for encephalopathy patients
      • 5.1.1.3. Impact of chronic diseases such as diabetes and hypertension on encephalopathy prevalence and management
      • 5.1.1.4. Integration of artificial intelligence in diagnosing and predicting the progression of neurological disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Integrating artificial intelligence in diagnosing various forms of encephalopathy
      • 5.1.3.2. Comprehensive patient education programs to improve encephalopathy treatment adherence
      • 5.1.3.3. Developing telemedicine platforms for remote encephalopathy patient management
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of disease mechanisms and diagnosis
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Encephalopathy Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Hepatic Encephalopathy
  • 6.3. Hypertensive Encephalopathy
  • 6.4. Toxic-Metabolic Encephalopathy
  • 6.5. Traumatic Encephalopathy
  • 6.6. Uremic Encephalopathy
  • 6.7. Wernicke's Encephalopathy

7. Encephalopathy Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Medications
    • 7.2.1. Antibiotics
    • 7.2.2. Lactulose
    • 7.2.3. Probiotics
    • 7.2.4. Rifaximin
  • 7.3. Surgery
    • 7.3.1. Liver Transplantation
    • 7.3.2. Neurosurgery
  • 7.4. Therapies
    • 7.4.1. Behavioral Therapy
    • 7.4.2. Cognitive Rehabilitation

8. Encephalopathy Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Research Institutes
  • 8.5. Specialty Clinics

9. Encephalopathy Market, by Severity

  • 9.1. Introduction
  • 9.2. Acute Encephalopathy
  • 9.3. Chronic Encephalopathy
  • 9.4. Subacute Encephalopathy

10. Encephalopathy Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Geriatric
  • 10.4. Pediatric

11. Encephalopathy Market, by Diagnosis Method

  • 11.1. Introduction
  • 11.2. Blood Tests
  • 11.3. Electroencephalogram (EEG)
  • 11.4. Imaging
    • 11.4.1. CT Scan
    • 11.4.2. MRI
    • 11.4.3. Ultrasound

12. Encephalopathy Market, by Application

  • 12.1. Introduction
  • 12.2. Diagnostic
  • 12.3. Research
  • 12.4. Therapeutic

13. Encephalopathy Market, by Pathophysiology

  • 13.1. Introduction
  • 13.2. Anoxic Encephalopathy
  • 13.3. Hypoxic Ischemic Encephalopathy

14. Americas Encephalopathy Market

  • 14.1. Introduction
  • 14.2. Argentina
  • 14.3. Brazil
  • 14.4. Canada
  • 14.5. Mexico
  • 14.6. United States

15. Asia-Pacific Encephalopathy Market

  • 15.1. Introduction
  • 15.2. Australia
  • 15.3. China
  • 15.4. India
  • 15.5. Indonesia
  • 15.6. Japan
  • 15.7. Malaysia
  • 15.8. Philippines
  • 15.9. Singapore
  • 15.10. South Korea
  • 15.11. Taiwan
  • 15.12. Thailand
  • 15.13. Vietnam

16. Europe, Middle East & Africa Encephalopathy Market

  • 16.1. Introduction
  • 16.2. Denmark
  • 16.3. Egypt
  • 16.4. Finland
  • 16.5. France
  • 16.6. Germany
  • 16.7. Israel
  • 16.8. Italy
  • 16.9. Netherlands
  • 16.10. Nigeria
  • 16.11. Norway
  • 16.12. Poland
  • 16.13. Qatar
  • 16.14. Russia
  • 16.15. Saudi Arabia
  • 16.16. South Africa
  • 16.17. Spain
  • 16.18. Sweden
  • 16.19. Switzerland
  • 16.20. Turkey
  • 16.21. United Arab Emirates
  • 16.22. United Kingdom

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2023
  • 17.2. FPNV Positioning Matrix, 2023
  • 17.3. Competitive Scenario Analysis
  • 17.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Biogen Inc
  • 7. Boehringer Ingelheim International GmbH
  • 8. Eisai Co., Ltd.
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis International AG
  • 15. Pfizer Inc.
  • 16. Roche Holdings AG
  • 17. Sanofi S.A.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. ENCEPHALOPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. ENCEPHALOPATHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ENCEPHALOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. ENCEPHALOPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. ENCEPHALOPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENCEPHALOPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENCEPHALOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENCEPHALOPATHY MARKET DYNAMICS
  • TABLE 7. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HYPERTENSIVE ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TOXIC-METABOLIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TRAUMATIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY UREMIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY WERNICKE'S ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LACTULOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RIFAXIMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY NEUROSURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY COGNITIVE REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ACUTE ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY CHRONIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SUBACUTE ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ELECTROENCEPHALOGRAM (EEG), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ANOXIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HYPOXIC ISCHEMIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 226. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 237. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 238. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. SINGAPORE ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 260. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 261. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 262. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. TAIWAN ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 272. THAILAND ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 273. THAILAND ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 274. THAILAND ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. THAILAND ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 282. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 283. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 284. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 285. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 286. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 287. VIETNAM ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. DENMARK ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 304. DENMARK ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 305. DENMARK ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 307. DENMARK ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 308. DENMARK ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 309. DENMARK ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 310. DENMARK ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 311. DENMARK ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 312. DENMARK ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 313. EGYPT ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. EGYPT ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. EGYPT ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 316. EGYPT ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 317. EGYPT ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 318. EGYPT ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 319. EGYPT ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 320. EGYPT ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 321. EGYPT ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 322. EGYPT ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 323. EGYPT ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. EGYPT ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 325. FINLAND ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. FINLAND ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. FINLAND ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 328. FINLAND ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 329. FINLAND ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 330. FINLAND ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 331. FINLAND ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 332. FINLAND ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 333. FINLAND ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 334. FINLAND ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 335. FINLAND ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 336. FINLAND ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 337. FRANCE ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 338. FRANCE ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 339. FRANCE ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 340. FRANCE ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 341. FRANCE ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 342. FRANCE ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 343. FRANCE ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 344. FRANCE ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 345. FRANCE ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 346. FRANCE ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 347. FRANCE ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 348. FRANCE ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 349. GERMANY ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 350. GERMANY ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 351. GERMANY ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 352. GERMANY ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 353. GERMANY ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 354. GERMANY ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 355. GERMANY ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 356. GERMANY ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 357. GERMANY ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 358. GERMANY ENCEPHALOPATHY MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 359. GERMANY ENCEPHALOPATHY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 360. GERMANY ENCEPHALOPATHY MARKET SIZE, BY PATHOPHYSIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 361. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 362. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 363. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 364. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 365. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 366. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 367. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 368. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 369. ISRAEL ENCEPHALOPATHY MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 370. ISRAEL ENCEPHALOPATH